Intracameral Cefuroxime in Combined Pars Plana Vitrectomy and Phacoemulsification



Post-operative endophthalmitis is a severe complication after intraocular surgery. Aim of this pilot study is to investigate the safety and efficacy of intracameral cefuroxime in combined vitrectomy and phacoemulsification for cataract and various vitreoretinal diseas.


Seventy-six charts of 76 patients who underwent combined phacoemulsification, intraocular lens implant and pars plana vitrectomy were reviewed. The final tamponade was chosen among fluid, air, gas or silicone oil, based on the requirement of each single case. Patients were operated by 4 different surgeons. At the end of surgery, 1mg/0.1ml of intracameral cefuroxime (Aprokam, Laboratoires Thea) was administered.


Mean follow-up was 6.267.78 months (range 1-12). No retinal complication, such as retinal infarction or hemorrhages were observed. No acute macular serous detachment and no new intraretinal cists were noted, in those patients who received OCT within the 5th day after surgery. No endophthalmitis was recorded.


Intracameral cefuroxime, at the end of combined phacoemulsification and pars plana vitrectomy, has no toxicity on the retina and should be considered effective in endophthalmitis prevention. Due to the relatively small number of patients, further studies are advisable.


Gianluca Besozzi
Brescia, Italy
Email :
Cell Phone: +393286153808
Work Phone: +393286153808